BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
    • Interviews
  • News
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Exosomes
  • CAR-T
  • Cord Blood
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » Aegle Therapeutics Prepares Phase 1/2a Trial of BM-MSC Derived Extracellular Vesicles
Aegle Therapeutics

Aegle Therapeutics Prepares Phase 1/2a Trial of BM-MSC Derived Extracellular Vesicles

July 20, 2018 By Cade Hildreth (CEO) Leave a Comment

Aegle TherapeuticsAegle Therapeutics Corporation is the first extracellular vesicle (EV) company to be cleared by the FDA to enter clinical trials in humans. Headquartered in Miami, FL, the company is using allogeneic bone marrow mesenchymal stem cell (BM-MSC) derived extracellular vesicles to treat severe dermatological disorders, with a focus on burn treatments.

Discover class-defining bioproduction tools.

In May 2018, Aegle announced that the FDA cleared its first Investigational New Drug (IND) application to initiate a clinical trial in severe second degree burn patients. The company plans to launch a Phase 1/2a clinical trial of its lead product AGLE-102 in late 2018.

The open label dose escalation study will enroll patients at several sites in the U.S., evaluating the safety of extracellular vesicle therapy in burn patients.

bitbio

Aegle Therapeutic’s Phase 1/2a Clinical Trial

According to Evangelos Badiavas, M.D., PhD, Aegle’s Founder and CSO, “We are excited to be moving our EV therapy into the clinic to treat burns, an indication with a substantial unmet medical need. We believe this product has the potential for functional regeneration and organization of complex tissue structures that can enhance healing, reduce scarring, minimize contraction and improve overall cosmesis. Currently, patients with burns suffer scarring, disfigurement, loss of mobility and chronic pain. There’s a real need for better therapies.”

According to Shelley Hartman, CEO of Aegle, “This achievement is an important step as the company launches a Series A capital raise in 2018 to fund its clinical development.”

iPSC-derived cardiomyocte therapy

Aegle Therapeutics Corporation

Aegle Therapeutics is a clinical-stage regenerative medicine company that is developing cell-free therapeutics. Its technology platform utilize a proprietary extracellular vesicle (EV) isolation technology that is “easy to scale, low cost and produces EVs with an extended shelf life.”

Pluristyx

The company is developing two products, AGLE-102 for the treatment of burns and scarring and AGLE-103 for the treatment of epidermolysis bullosa (EB). EB is a a genetic condition that causes the skin to be fragile and blister.

Aegle Therapeutics’ announcement about receiving FDA clearance for its IND involving the use of a MSC-derived extracellular vesicle therapy for burn victims is available here.

To learn more about the exosome market, view our 134-page global strategic report the “Market for Stem Cell Exosomes.”

Do you have questions about Aegle Therapeutics? Ask them in the comments below.

4.8/5 - (9 votes)

Filed Under: Exosomes, Stem Cell News

Related

About Cade Hildreth (CEO)

Cade Hildreth is the Founder of BioInformant.com, the world's largest publisher of stem cell industry news. Cade is a media expert on stem cells, recently interviewed by the Wall Street Journal, Los Angeles Business Journal, Xconomy, and Vogue Magazine. 

Tell Us What You Think! Cancel reply

Nanocellect

Marathon Products

Let’s Get Social

  • Facebook
  • Twitter
  • LinkedIn
  • Pinterest
  • Instagram
Menu
  • Blog
  • Stem Cell News
    • Press Releases
  • Stem Cells
    • HSCs
    • iPS Cells
    • MSCs
    • Neural Stem Cells
    • Adipose SCs
  • Exosomes
  • Cell Therapy
    • CAR-T
  • Cord Blood
  • Interviews

Cart

Featured Posts

PolarityTE RMAT

PolarityTE Announces FDA RMAT Awarded to Its Designation Granted to SkinTE®

Advanced Therapy | What is a RMAT Designation (and Who Has One)?

What Is An RMAT? List of Publicly Announced RMAT Designations (64)

i-peaces-cell-manufacturing

I Peace accelerates allogeneic iPSC-derived cell therapies with a high throughput method to identify a large number of donors with specific HLA haplotypes

My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2022 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: Info@BioInformant.com | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.